Role of 18F-FDG PET/CT in the Carcinoma of the Uterus: A Review of Literature

키워드

참고문헌 (45)

1. "What are the key statistics about cervical cancer?"[URL]
2. "What are the key statistics about endometrial cancer?"[URL]
3. "GLOBOCAN 2012"[URL]
4. Colombo N, "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 23(Suppl 7), pp.vii27~vii32 (2012)
5. Colombo N, "Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.vi33~vi38 (2013)
6. Sala E, "Advances in magnetic resonance imaging of endometrial cancer", Eur Radiol, 21, pp.468~473 (2011)
7. Rey-Ares L, "Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis", Arch Argent Pediatr, 110, pp.483~489 (2012)
8. Edge SB, "AJCC cancer staging manual. 7th ed", pp.403~418 (2010), Springer
9. Cheng X, "The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery", World J Surg Oncol, 2, pp.47~ (2004)
10. Aoki Y, "High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation", Gynecol Oncol, 77, pp.305~309 (2000)
11. Pecorelli S, "Revised FIGO staging for carcinoma of the cervix", Int J Gynaecol Obstet, 105, pp.107~108 (2009)
12. Bum Soo Kim, "The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET", CT, 2011, pp.45(1), 36~42[DOI]
13. Sironi S, "Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET", CT, 2006, pp.238, 272~279
14. Gouy S, "Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging", J Clin Oncol, 31, pp.3026~3033 (2013)
15. Nakamura K, "Maximum standardized lymph node uptake value could be an important predictor of recurrence and survival in patients with cervical cancer", Eur J Obstet Gynecol Reprod Biol, 173, pp.77~82 (2014)
16. Chung HH, "Preoperative PET", CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer, 2014, pp.41, 674~681
17. Im HJ, "Prognostic implication of retrocrural lymph node involvement revealed by (18)F-FDG PET", CT in patients with uterine cervical cancer, 2014, pp.35, 268~275
18. Kidd EA, "Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer", Cancer, 116, pp.1469~1475 (2010)
19. Kitajima K, "Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET", CT and pelvic MRI, 2014, pp.38, 464~469
20. Nakajo K, "Diagnostic performance of fluorodeoxyglucose positron emission tomography", magnetic resonance imaging fusion images of gynecological malignant tumors: comparison with positron emission tomography, Jpn J Radiol, pp.2010, 28[DOI]
21. Hicks RJ, "The role of PET in monitoring therapy", Cancer Imaging, 5, pp.51~57 (2005)
22. Avril N, "Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer", J Clin Oncol, 23, pp.7445~7453 (2005)
23. Nishiyama Y, "Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET", Eur J Nucl Med Mol Imaging, 35, pp.287~295 (2008)
24. fluorodeoxyglucose-positron emission tomography, "computed tomography", Int J Radiat Oncol Biol Phys, 84, pp.e491~e497 (2012)
25. Oh D, "Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography", computed tomography during concurrent chemoradiation therapy for cervical cancer, 2013, pp.87, 549~554
26. Kidd EA, "Changes in cervical cancer FDG uptake during chemoradiation and association with response", Int J Radiat Oncol Biol Phys, 85, pp.116~122 (2013)
27. Chung HH, "Clinical impact of integrated PET", CT on the management of suspected cervical cancer recurrence, 2007, pp.104(3), 529~534
28. Mittra E, "Efficacy of 18F-FDG PET", CT in the evaluation of patients with recurrent cervical carcinoma, 2009, pp.36, 1952~1959
29. Sironi S, "Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET", CT in the detection of recurrence, 2007, pp.34, 472~479
30. Kitajima K, "Performance of FDG-PET", CT for diagnosis of recurrent uterine cervical cancer, 2008, pp.18, 2040~2047
31. Benedetti Panici P, "Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial", J Natl Cancer Inst, 100, pp.1707~1716 (2008)
32. Dowdy SC, "Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer", Gynecol Oncol, 127, pp.5~10 (2012)
33. Antonsen SL, "MRI, PET", CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study, 2013, pp.128, 300~308
34. Kitajima K, "Accuracy of 18F-FDG PET", CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer, 2008, pp.190, 1652~1658
35. Nayot D, "Does preoperative positron emission tomography with computed tomography predict nodal status in endometrial cancer? A pilot study", Curr Oncol, 15, pp.123~125 (2008)
36. Crivellaro C, "Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET", CT, 2013, pp.130, 306~311
37. Nakamura K, "The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer", Gynecol Oncol, 123, pp.82~87 (2011)
38. Nakamura K, "The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer", Eur J Nucl Med Mol Imaging, 40, pp.52~60 (2013)
39. Kitajima K, "Value of fusion of PET and MRI for staging of endometrial cancer: comparison with 18F-FDG contrast-enhanced PET", CT and dynamic contrast-enhanced pelvic MRI, 2013, pp.82, 1672~1676
40. Boers-Sonderen MJ, "Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET", CT, 2014, ~
41. FDG PET, "CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings", Eur J Nucl Med Mol Imaging, 35, pp.1081~1088 (2008)
42. Park JY, "Clinical impact of positron emission tomography or positron emission tomography", computed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients, 2008, pp.18, 1332~1338
43. Sharma P, "Carcinoma endometrium: role of 18-FDG PET", CT for detection of suspected recurrence, 2012, pp.37, 649~655
44. Ozcan Kara P, "The value of FDG-PET", CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET, Rev Esp Med Nucl Imagen Mol, pp.2012, 31[DOI]
45. Kitajima K, "Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET", CT studies for the diagnosis of uterine cancer recurrence, 2010, pp.37, 1490~1498

관련 논문AI추천